Mga Batayang Estadistika
| CIK | 1124608 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Response Genetics, Inc
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 16, 2016 |
RGDXQ / Response Genetics, Inc. / 12 West Capital Management LP - AMENDMENT NO. 5 Passive Investment SC 13G/A 1 response13gam5dec2015.htm AMENDMENT NO. 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* RESPONSE GENETICS, INC. (Name of Issuer) Common Stock, $0.01 par value PER SHARE (Title of Class of Securities) 76123U105 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this S |
|
| February 12, 2016 |
RGDXQ / Response Genetics, Inc. / LANSDOWNE PARTNERS (UK) LLP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. |
|
| November 20, 2015 |
RGDXQ / Response Genetics, Inc. / BRIDGER MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) RESPONSE GENETICS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 76123U105 (CUSIP Number) November 18, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| October 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2015 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-33509 Delaware 11-3525548 (State or other jurisdiction of inco |
|
| October 5, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2015 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-33509 Delaware 11-3525548 (State or other jurisdiction of (IRS |
|
| August 26, 2015 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2015 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-33509 Delaware 11-3525548 (State or other jurisdiction of (IRS |
|
| August 11, 2015 |
8-K 1 v4176958k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2015 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-33509 Delaware 11-3525548 (State o |
|
| August 11, 2015 |
Exhibit 10.2 Response Genetics, Inc. Terms and Conditions of Proposed Senior Secured, Super-Priority Debtor-in-Possession Credit Facility The terms outlined below in this Terms and Conditions (this ?DIP Term Sheet?) are the terms and conditions for a senior secured, super-priority debtor-in-possession credit facility (hereinafter referred to as the ?DIP Facility?) to be made available to the Debto |
|
| August 11, 2015 |
Exhibit 10.1 ASSET PURCHASE AGREEMENT BY AND BETWEEN RESPONSE GENETICS, INC., A DELAWARE corporation AND CANCER GENETICS, INC., a DELAWARE CORPORATION Dated as of AUGUST 9, 2015 Table of Contents Page 1. Purchase and Sale 1 1.1 Assets to Be Transferred 1 1.2 Excluded Assets 3 1.3 Liabilities 5 1.4 Purchase Price; Deposit; and Allocation of Purchase Price 7 1.5 Closing 8 1.6 Closing Deliveries by S |
|
| July 6, 2015 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2015 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction of |
|
| July 1, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2015 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction of |
|
| July 1, 2015 |
THIRD AMENDMENT TO CREDIT AGREEMENT Exhibit 10.1 THIRD AMENDMENT TO CREDIT AGREEMENT THIS THIRD AMENDMENT TO CREDIT AGREEMENT (this ?Amendment?), dated as of June 25, 2015, is entered into by and among Response Genetics, Inc., a Delaware corporation (?Borrower?), each of the undersigned financial institutions party hereto as lenders (individually each a ?Lender? and collectively ?Lenders?), and SWK FUNDING LLC, a Delaware limited li |
|
| May 15, 2015 |
RGDX FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33509 RESPONSE GEN |
|
| May 14, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2015 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction of |
|
| May 14, 2015 |
Response Genetics, Inc. Announces First Quarter 2015 Financial Results EX-99.1 2 v410705ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A. Bologna Trout Group Chairman & Chief Executive Officer 646-378-2973 323-224-3900 Response Genetics, Inc. Announces First Quarter 2015 Financial Results LOS ANGELES, May 14, 2015 — Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development |
|
| April 8, 2015 |
RGDXQ / Response Genetics, Inc. / BRIDGER MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) RESPONSE GENETICS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 76123U105 (CUSIP Number) April 3, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| April 8, 2015 |
SECOND AMENDMENT TO CREDIT AGREEMENT Exhibit 10.1 SECOND AMENDMENT TO CREDIT AGREEMENT THIS SECOND AMENDMENT TO CREDIT AGREEMENT (this ?Amendment?), dated as of April 3, 2015, is entered into by and among Response Genetics, Inc., a Delaware corporation (?Borrower?), each of the undersigned financial institutions party hereto as lenders (individually each a ?Lender? and collectively ?Lenders?), and SWK FUNDING LLC, a Delaware limited |
|
| April 8, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2015 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction of |
|
| March 31, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 v4061778-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2015 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other jurisdiction of |
|
| March 31, 2015 |
EX-99.1 2 v406177ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A. Bologna Trout Group Chairman & Chief Executive Officer 646-378-2973 323-224-3900 Response Genetics, Inc. Announces Fourth Quarter and Year-End 2014 Financial Results Response DX Revenue increased 16% and 22% over Fourth Quarter and Full Year 2013 Respectiv |
|
| March 20, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2015 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction o |
|
| February 17, 2015 |
RGDXQ / Response Genetics, Inc. / 12 West Capital Management LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* RESPONSE GENETICS, INC. (Name of Issuer) Common Stock, $0.01 par value PER SHARE (Title of Class of Securities) 76123U105 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 6, 2015 |
FIRST AMENDMENT TO CREDIT AGREEMENT Exhibit 10.1 FIRST AMENDMENT TO CREDIT AGREEMENT THIS FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of February 3, 2015, is entered into by and among Response Genetics, Inc., a Delaware corporation (“Borrower”), each of the undersigned financial institutions (individually each a “Lender” and collectively “Lenders”) and SWK FUNDING LLC, a Delaware limited liability company, in it |
|
| February 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2015 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction |
|
| January 29, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2014 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Empl |
|
| January 29, 2015 |
EX-10.1 2 v399569ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 EXECUTION VERSION CREDIT AGREEMENT among Response genetics, inc., as Borrower, SWK FUNDING LLC, as Agent, Sole Lead Arranger and Sole Bookrunner, and the financial institutions party hereto from time to time as Lenders Dated as of July 30, 2014 [ResGen] Credit Agreement Table of Contents Page Section 1 Definitions; Interpretation 1 1.1 Definiti |
|
| December 24, 2014 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2014 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other jurisdiction of incorporation) (Commission |
|
| November 26, 2014 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8-K 1 v3954038-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2014 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other jurisdiction |
|
| November 13, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2014 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdictio |
|
| November 13, 2014 |
EX-99.1 2 v394176ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A. Bologna Trout Group Chairman & Chief Executive Officer 646-378-2973 323-224-3900 Response Genetics, Inc. Announces Third Quarter 2014 Financial Results -ResponseDX® quarterly revenues increase 54% over prior year - LOS ANGELES, November 13, 2014 — Response |
|
| October 1, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2014 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdicti |
|
| October 1, 2014 |
AMENDMENT NO. 1 EMPLOYMENT AGREEMENT EX-10.1 2 v390433ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This Amendment No. 1 (“Amendment”) to the Agreement (defined below) is entered into as of September 25, 2014 between Thomas A. Bologna (“Executive”) and Response Genetics, Inc., a Delaware corporation (the “Company”). WHEREAS, the Company and Executive are parties to that certain employment agreement date |
|
| August 14, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 v3867788k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2014 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission Fil |
|
| August 14, 2014 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A. Bologna Trout Group Chairman & Chief Executive Officer 646-378-2973 323-224-3900 Response Genetics, Inc. Announces Second Quarter 2014 Financial Results -ResponseDX® Revenue sets record for quarterly DX sales as testing volume again increases over prior quarter - LOS ANGELES, August 14, 2014 — Re |
|
| August 12, 2014 |
As filed with the Securities and Exchange Commission on August 12, 2014 Registration No. |
|
| August 5, 2014 |
EX-10.1 2 v385757ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 EXECUTION VERSION CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS AGREEMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH THREE ASTERISKS (***), HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CREDIT AGREEMENT among Response genetics, inc., as Borrower, SWK FUNDING LLC, as Ag |
|
| August 5, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2014 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 21, 2014 |
As filed with the Securities and Exchange Commission on July 21, 2014 Registration No. |
|
| July 15, 2014 |
EX-3.1 2 v383790ex3-1.htm EXHIBIT 3.1 |
|
| July 15, 2014 |
8-K 1 v3837908-k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2014 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS |
|
| July 11, 2014 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2014 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction of |
|
| July 10, 2014 |
RGDXQ / Response Genetics, Inc. / LANSDOWNE PARTNERS AUSTRIA GMBH Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. |
|
| June 24, 2014 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2014 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction of |
|
| May 27, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| May 27, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| May 8, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2014 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction of N |
|
| May 8, 2014 |
FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A. |
|
| April 4, 2014 |
SC 13D/A 1 d706538dsc13da.htm SCHEDULE 13D AMENDEMENT NO. 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7) * RESPONSE GENETICS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 76123U105 (CUSIP Number) Becker Drapkin Management, L.P. Attn: Steven R. Becker Attn: Matth |
|
| March 31, 2014 |
RGDX FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-33509 RESPONSE GENETICS, INC. (Exact |
|
| March 20, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2014 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 20, 2014 |
Response Genetics, Inc. Announces Fourth Quarter and Year-End 2013 Financial Results FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A. |
|
| February 14, 2014 |
RGDXQ / Response Genetics, Inc. / 12 West Capital Management LP - AMENDMENT NO. 3 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* RESPONSE GENETICS, INC. (Name of Issuer) COMMON STOCK, $0.01 PAR VALUE PER SHARE (Title of Class of Securities) 76123U105 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 14, 2014 |
Schedule 13D Amendment No. 6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6) * RESPONSE GENETICS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 76123U105 (CUSIP Number) Becker Drapkin Management, L.P. Attn: Steven R. Becker Attn: Matthew A. Drapkin 500 Crescent Cour |
|
| February 14, 2014 |
RGDXQ / Response Genetics, Inc. / LANSDOWNE PARTNERS LIMITED PARTNERSHIP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. |
|
| January 13, 2014 |
RGDXQ / Response Genetics, Inc. / BRIDGER MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) RESPONSE GENETICS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 76123U105 (CUSIP Number) January 2, 2014 (Date of Event which requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| December 13, 2013 |
4,464,443 Shares RESPONSE GENETICS, INC. Common Stock UNDERWRITING AGREEMENT 4,464,443 Shares RESPONSE GENETICS, INC. Common Stock UNDERWRITING AGREEMENT December 13, 2013 NATIONAL SECURITIES CORPORATION 410 Park Avenue, 14th Floor New York, NY 10022 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Response Genetics, Inc., a Delaware corporation (the “Company”), hereby agrees to issue and sell to National Securities Corpora |
|
| December 13, 2013 |
Response Genetics, Inc. Announces Pricing of Underwritten Public Offering FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A. |
|
| December 13, 2013 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-171266 PROSPECTUS SUPPLEMENT To Prospectus dated January 6, 2011 4,464,443 Shares Response Genetics, Inc. Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 4,464,443 shares of our common stock at a public offering price of $1.20 per share. Our common stock is quoted on The NASDAQ Capital Market |
|
| December 13, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2013 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdictio |
|
| December 12, 2013 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2013 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdictio |
|
| December 12, 2013 |
RESPONSE GENETICS, INC. FREE WRITING PROSPECTUS ISSUER FREE WRITING PROSPECTUS Dated December 12, 2013 Filed Pursuant to Rule 433 Registration No. |
|
| December 12, 2013 |
Response Genetics, Inc. Announces Proposed Underwritten Public Offering EX-99.1 2 v362818ex99-1.htm EXHIBIT 99.1 FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A. Bologna Trout Group Chairman & Chief Executive Officer 646-378-2973 323-224-3900 Response Genetics, Inc. Announces Proposed Underwritten Public Offering LOS ANGELES, December 12, 2013 — Response Genetics, Inc. (Nasdaq: RGDX) (the “Company”), a company focused on the de |
|
| December 12, 2013 |
The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| November 25, 2013 |
Submission of Matters to a Vote of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2013 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdictio |
|
| November 7, 2013 |
Response Genetics, Inc. Announces Third Quarter 2013 Financial Results FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A. |
|
| November 7, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2013 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction |
|
| October 8, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| October 8, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| September 30, 2013 |
Response Genetics, Inc. 1640 Marengo Street, 6th Floor Los Angeles, CA 90033 September 30, 2013 VIA EDGAR AND FEDEX Mr. Jeffrey P. Riedler Assistant Director United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Response Genetics, Inc. Form 10-K Filed March 27, 2013 File No. 001-33509 Dear Mr. Riedler: Reference is made to th |
|
| September 25, 2013 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2013 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdicti |
|
| September 24, 2013 |
932,805 Shares Response Genetics, Inc. Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-171266 PROSPECTUS SUPPLEMENT To Prospectus dated January 6, 2011 932,805 Shares Response Genetics, Inc. Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering an aggregate of up to 932,805 shares of our common stock directly to investors at a price per share of $2.05. Our common stock is quoted on T |
|
| September 20, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2013 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdicti |
|
| September 20, 2013 |
Exhibit 10.1 PLACEMENT AGENCY AGREEMENT September 19, 2013 Ladenburg Thalmann & Co. Inc. 520 Madison Avenue New York, NY 10022 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Response Genetics, Inc., a Delaware corporation (the “Company”), hereby agrees to sell an aggregate of $1,912,250.25 of registered securities (the “Securities”) of the Compan |
|
| September 20, 2013 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A. Bologna Trout Group Chairman & Chief Executive Officer 646-378-2973 323-224-3900 Response Genetics, Inc. Announces $1.9 Million Registered Direct Offering -Proceeds to be used for launch of recently acquired FDA-Cleared and Medicare-reimbursed test for difficult to diagnose tumors- LOS ANGELES, S |
|
| August 26, 2013 |
8-K 1 v3537108-k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2013 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commiss |
|
| August 26, 2013 |
EXHIBIT 10.1 EXECUTION VERSION ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (the “Agreement”) is hereby entered into on August 23, 2013 (the “Effective Date”), by and between Pathwork (assignment for the benefit of creditors), LLC(“Seller”), a California limited liability company, in its sole and limited capacity as assignee for the benefit of creditors of Pathwork Diagnostics, Inc., wit |
|
| August 26, 2013 |
EX-99.1 3 v353710ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A. Bologna Trout Group Chairman & Chief Executive Officer 646-378-2973 323-224-3900 Response Genetics, Inc. Acquires Proprietary FDA-Cleared and Medicare-Reimbursed Test and All Associated Assets for Difficult to Diagnose Solid Tumors - Acquisition expected t |
|
| August 23, 2013 |
500,000 Shares Response Genetics, Inc. Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-171266 PROSPECTUS SUPPLEMENT To Prospectus dated January 6, 2011 500,000 Shares Response Genetics, Inc. Common Stock Response Genetics, Inc. is offering an aggregate of 500,000 shares of its common stock all of which will be issued directly to certain designees of Pathwork (assignment for the benefit of creditors), LLC (“Seller”). The shares of |
|
| August 8, 2013 |
FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A. |
|
| August 8, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2013 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction o |
|
| July 26, 2013 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* RESPONSE GENETICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 76123U105 (CUSIP Number) Becker Drapkin Management, L.P. Attn: Steven R. Becker 500 Crescent Court, Suite 230 Dallas, Texas 75201 (214) 756-6016 (Name, Address |
|
| June 17, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2013 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction of |
|
| June 17, 2013 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of June 12, 2013 (the “Effective Date”) between Response Genetics, Inc., a Delaware Corporation (the “Company”) and Kevin R. Harris (“Executive”). WHEREAS, Executive has served as Interim Chief Financial Officer of the Company since August 20, 2012; and WHEREAS, Executive and the Company desire to enter into this |
|
| May 14, 2013 |
FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A. |
|
| May 14, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2013 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other jurisdiction of incorporation) (Commission File |
|
| March 21, 2013 |
FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A. |
|
| March 21, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2013 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction o |
|
| February 14, 2013 |
RGDXQ / Response Genetics, Inc. / 12 West Capital Management LP - AMENDMENT NO. 2 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* RESPONSE GENETICS, INC. (Name of Issuer) COMMON STOCK, $0.01 PAR VALUE PER SHARE (Title of Class of Securities) 76123U105 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 14, 2013 |
RGDXQ / Response Genetics, Inc. / LANSDOWNE PARTNERS LIMITED PARTNERSHIP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. |
|
| November 13, 2012 |
FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A. |
|
| November 13, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdictio |
|
| November 13, 2012 |
8,000,000 Shares RESPONSE GENETICS, INC. Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-184614 PROSPECTUS 8,000,000 Shares RESPONSE GENETICS, INC. Common Stock This prospectus covers 8,000,000 shares of common stock of Response Genetics, Inc. (“RGI”) that may be sold or otherwise disposed of from time to time by the selling stockholders named herein, or their transferees. We will not receive any of the proceeds from such sales. Th |
|
| October 26, 2012 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 26, 2012 REGISTRATION NO. |
|
| October 10, 2012 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction |
|
| October 10, 2012 |
Response Genetics Regains Compliance with NASDAQ Listing Standards FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A. |
|
| October 3, 2012 |
Amendment No.1 to Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) RESPONSE GENETICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 76123U105 (CUSIP Number) September 13, 2012 (Date of Event which requires Filing of this Statement) Check the appropriate box to designate |
|
| September 21, 2012 |
RGDXQ / Response Genetics, Inc. / GLAXOSMITHKLINE PLC Passive Investment SC 13G 1 glaxorg-13g0921.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Response Genetics, Inc. (Name of Issuer) Common Stock, Par Value $0.01 |
|
| September 19, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-1124608 11-3525548 (State or other (Commission File (IRS Employer jurisd |
|
| September 19, 2012 |
Exhibit 10.1 EXECUTION VERSION PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (this “Agreement”) is made as of the 13th day of September, 2012, by and among Response Genetics, Inc., a Delaware corporation (the “Company”), and the investors set forth in Exhibit A hereto (each an “Investor” and collectively, the “Investors”). Recitals A. The Company and each Investor are executing and delivering this Ag |
|
| September 19, 2012 |
Exhibit 10.2 EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (the “Agreement”) is made and entered into as of this 13th day of September, 2012, by and among Response Genetics, Inc., a Delaware corporation (the “Company”), and each investor set forth on the signature pages hereto and any Affiliate or permitted transferee of any such investor who is a subsequent ho |
|
| September 19, 2012 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A. Bologna Trout Group Response Genetics, Inc. 646-378-2973 323-276-6060 Response Genetics Raises $8.8 Million in Financing Company to Present at UBS Global Life Sciences in NYC on September 20, 2012 LOS ANGELES, September 13, 2012 – Response Genetics, Inc. (Nasdaq: RGDX) announced today that it has |
|
| August 21, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-1124608 11-3525548 (State or other (Commission File (IRS Employer jurisdict |
|
| August 21, 2012 |
EXHIBIT 10.1 Response Genetics 1640 Marengo St., 6th Floor Los Angeles, CA 90033 Telephone: (323) 224-3900 Facsimile: (323) 224-3094 August 15, 2012 Via Email Kevin Harris [Address Redacted] RE: Temporary Employment with Response Genetics, Inc. Dear Kevin: It is with pleasure that we offer you a temporary position as Interim CFO for Response Genetics, Inc. (“RGI”). You have the talent and training |
|
| August 14, 2012 |
EX-99.1 2 v321317ex99-1.htm EXHIBIT 99.1 FOR IMMEDIATE RELEASE Investor Relations Contact: Media Relations Contact: Peter Rahmer Barry Sudbeck Trout Group Fleishman-Hillard 646-378-2956 415-318-4261 Response Genetics, Inc. Announces Second Quarter Financial Results - Second consecutive quarter of decreased net loss and increased gross margin - LOS ANGELES, August 14, 2012 — Response Genetics, Inc. |
|
| August 14, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-1124608 11-3525548 (State or other (Commission File (IRS Employer jurisdict |
|
| August 3, 2012 |
Submission of Matters to a Vote of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-1124608 11-3525548 (State or other (Commission File (IRS Employer jurisdictio |
|
| August 1, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-1124608 11-3525548 (State or other (Commission File (IRS Employer jurisdictio |
|
| August 1, 2012 |
SECOND AMENDED AND RESTATED MASTER SERVICES AGREEMENT Exhibit 10.1 Portions of this Exhibit have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. Such portions are marked by [***]. Confidential SECOND AMENDED AND RESTATED MASTER SERVICES AGREEMENT PREAMBLE Thi |
|
| July 20, 2012 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-1124608 11-3525548 (State or other (Commission File (IRS Employer jurisdictio |
|
| June 18, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| June 18, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| May 29, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-1124608 11-3525548 (State or other (Commission File (IRS Employer jurisdiction |
|
| May 17, 2012 |
5,257,267 Shares RESPONSE GENETICS, INC. Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-181045 PROSPECTUS 5,257,267 Shares RESPONSE GENETICS, INC. Common Stock This prospectus covers up to 5,257,267 shares of common stock of Response Genetics, Inc. (“RGI”) that may be sold or otherwise disposed of from time to time by the selling stockholders named herein, or their transferees. We will not receive any of the proceeds from such sal |
|
| May 10, 2012 |
Response Genetics, Inc. Announces First Quarter Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations Contact: Media Relations Contact: Michaela Parnell Barry Sudbeck Trout Group Fleishman-Hillard 646-378-2956 415-318-4261 Response Genetics, Inc. Announces First Quarter Financial Results LOS ANGELES, May 10, 2012 — Response Genetics Inc. (Nasdaq: RGDX), (the “Company”), a company focused on the development and sale of molecular diagnostic tests |
|
| May 10, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-1124608 11-3525548 (State or other (Commission File (IRS Employer jurisdiction |
|
| April 30, 2012 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON APRIL 30, 2012 REGISTRATION NO. |
|
| April 24, 2012 |
RGDXQ / Response Genetics, Inc. / 12 West Capital Management LP - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* RESPONSE GENETICS, INC. (Name of Issuer) COMMON STOCK, $0.01 PAR VALUE PER SHARE (Title of Class of Securities) 76123U105 (CUSIP Number) April 16, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| April 20, 2012 |
RGDXQ / Response Genetics, Inc. / 12 West Capital Management LP - RESPONSE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* RESPONSE GENETICS, INC. (Name of Issuer) COMMON STOCK, $0.01 PAR VALUE PER SHARE (Title of Class of Securities) 76123U105 (CUSIP Number) April 16, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| April 2, 2012 |
SEC FILE NUMBER 001-33509 CUSIP NUMBER 76123U105 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 28, 2012 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations Contact: Media Relations Contact: Michaela Parnell Barry Sudbeck Trout Group Fleishman-Hillard 646-378-2956 415-318-4261 Response Genetics, Inc. Announces Year-End and Fourth Quarter Financial Results 2011 ResponseDX® Revenues increase over 2010 LOS ANGELES, March 27, 2012 — Response Genetics Inc. (Nasdaq: RGDX), a company focused on the develo |
|
| March 28, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-1124608 11-3525548 (State or other (Commission File (IRS Employer jurisdicti |
|
| March 7, 2012 |
RGDXQ / Response Genetics, Inc. / Serruya Samuel - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 Response Genetics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 76123U 105 (CUSIP Number) December 31, 2011 (Dat |
|
| February 21, 2012 |
Response Genetics Regains NASDAQ Compliance Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations Contact: Media Relations Contact: Michaela Parnell Barry Sudbeck The Trout Group LLC Fleishman-Hillard 646-378-2956 415-318-4261 Response Genetics Regains NASDAQ Compliance LOS ANGELES, February 21, 2012 – Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, announced to |
|
| February 21, 2012 |
Financial Statements and Exhibits, Other Events - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-1124608 11-3525548 (State or other (Commission File (IRS Employer jurisdi |
|
| February 13, 2012 |
RGDXQ / Response Genetics, Inc. / BRIDGER MANAGEMENT, LLC - SCHEDULE 13G Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 RESPONSE GENETICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 76123U105 (CUSIP Number) February 2, 2012 (Date of Event which requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| February 13, 2012 |
RGDXQ / Response Genetics, Inc. / LANSDOWNE PARTNERS LIMITED PARTNERSHIP Passive Investment OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response………11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. |
|
| February 6, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-1124608 11-3525548 (State or other (Commission File (IRS Employer jurisdic |
|
| February 6, 2012 |
FORM OF REGISTRATION RIGHTS AGREEMENT Exhibit 10.2 FORM OF REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (the “Agreement”) is made and entered into as of this 2nd day of February, 2012, by and among Response Genetics, Inc., a Delaware corporation (the “Company”), and the “Investor” named in that certain Purchase Agreement, by and among the Company and the Investor, dated as of the date hereof (the “Purchase Agreemen |
|
| February 6, 2012 |
Exhibit 10.1 FORM OF PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (this “Agreement”) is made as of the 2nd day of February, 2012, by and among Response Genetics, Inc., a Delaware corporation (the “Company”), and (the “Investor”). Recitals A. The Company and the Investor are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by the provisions |
|
| February 6, 2012 |
AMENDMENT NO. 4 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* RESPONSE GENETICS, INC. (Name of issuer) Common Stock (Title of class of securities) 76123U105 (CUSIP number) Becker Drapkin Management, L.P. Attn: Steven R. Becker 300 Crescent Court, Suite 1111 Dallas, Texas 75201 (214) |
|
| January 12, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No 2) Response Genetics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 76123U105 (CUSIP Number) October 7, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
